Doxazosin, an a 1 -adrenergic receptor inhibitor, is commonly administered to patients with type 2 diabetes, hypertension and nephropathy. The impact of 3 months' doxazosin therapy on the prevalence of activated and regulatory T lymphocytes was analysed in this pilot study of men with type 2 diabetes (n = 10) who received doxazosin 4 mg/day in addition to their ongoing therapy. 
Introduction
Current guidelines recommend the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in diabetic patients with microalbuminuria. 1 These agents prevent cardiovascular and renal morbidity 2 and allcause mortality. 3 The protection provided is proportional to the improvement of proteinuria. 4 Some patients do not, however, respond sufficiently. This situation requires the introduction of another antihypertensive agent. 5 Doxazosin, a selective α 1 -adrenergic receptor blocker, is used widely for this purpose as it improves morning surge hypertension, decreases albuminuria in patients with type 2 diabetes, 6 and results in improvements of left ventricular mass index, plasminogen-activator inibitor-1 levels, lipid profiles, blood glucose control and endothelial dependent vasodilation. 7, 8 Studies have also reported immunomodulatory actions of doxazosin. For example, in hypertensive patients, high sensitivity C-reactive protein (hsCRP) has been shown to decrease after 4 months of doxazosin therapy. 9 Doxazosin has also E Mácsai, Á Cseh, G Budai et al.
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been shown to increase intracellular adhesion molecule-1 and CD40 expression, and interleukin-18 production by human peripheral monocytes, suggesting the modulation of innate immunity. 10 There are no data on the impact of doxazosin on adaptive immunity. EpsteinBarr virus has been shown to transform B lymphocyte surface expression of α 1 -and α 2 -receptors, 11, 12 providing a theoretical opportunity to study the immunomodulatory action of α 1 -adrenergic receptor blockers. Prazosin, another member of this pharmaceutical class, has been shown to delay the progression of autoimmune encephalitis (a T-cell mediated disorder) in animals. 13 The present pilot study was designed to evaluate the effect of doxazosin on the prevalence of activated CD4 + 
STUDY DESIGN AND ASSESSMENTS
Patients' systolic and diastolic blood pressures and clinical chemistry were obtained at visit 1, before administration of doxazosin 4 mg once a day (Cardura ® XL; Pfizer, New York, NY, USA), which uses a gastrointestinal therapeutic system (GITS) to provide a controlled rate of drug delivery into the gastrointestinal lumen. The dose regimens of any other drugs at baseline were to remain unchanged during the study. After 3 months of treatment, patients' blood pressure and clinical chemistry were reassessed (visit 2).
On visits 1 and 2, 5 ml of blood was taken into commercially available heparincontaining tubes (BD Vacutainer ® ; Becton Dickinson & Co., Plymouth, UK). Peripheral blood mononuclear cells were separated from whole blood using a Ficoll-Paque™ Plus gradient (GE Healthcare Bio-Sciences, Uppsala, Sweden) within 6 h after sampling as previously described 14 and stored at -80°C until measurements were carried out (within 1 month). Patients' systolic and diastolic blood pressures and clinical chemistry, including glycated haemoglobin (Hb A1c ), total cholesterol, low-density lipoproteincholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglyceride levels, microalbuminuria, high sensitivity C-reactive protein (hsCRP) plasma concentration, and estimated glomerular filtration rate (Cockcroft-Gault method), were assessed at both visits. At visits 1 and 2, measurement of intracellular FoxP3 and detection of CD4, CD8, CD25 and CD69 cell surface markers were performed as described previously. 14 Blood pressure was measured at visits 1 and 2 by ambulatory blood pressure monitoring.
For measurement of microalbuminuria, 200 ml of 24-h urine was used in an immunoassay method (Tinaquant albumin immunoturbidimetric assay (Roche Diagnostics, Basel, Switzerland).
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The prevalence of different cell types before and after 3 months of doxazosin therapy was compared using the paired nonparametric Wilcoxon test. A P-value < 0.05 was considered to be statistically significant. Statistical analysis were carried out using the 'R' software package (The 'R' Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org).
Results
A total of 10 men with type 2 diabetes were enrolled into this study. Their baseline clinical characteristics and baseline therapies are shown in Table 1 . 
Discussion
The main finding of this pilot study was that 3 months of therapy with doxazosin 4 mg once a day was associated with an improvement in cardiovascular risk factors and changes in adaptive immunity (a decrease in the prevalence of activated lymphocytes and an increase in the prevalence of regulatory CD4 + lymphocytes) in patients with type 2 diabetes. The beneficial effects of doxazosin used as a second-or third-line agent on cardiovascular risk factors have been demonstrated in different hypertensive patient populations (including patients with diabetes, obesity and hypercholesterolaemia) in a large meta-analysis. 15 Indeed, even in the small patient population used in the present study a significant decrease in morning surge and daytime hypertension was observed, as well as an improvement in proteinuria, lipid profile and blood glucose control. These findings are in line with previous observations. 6, 7 The immunomodulatory action of doxazosin is a novel observation. The pharmaceutical target of doxazosin, α 1 -adrenergic receptors, are expressed by not only the vascular wall, but also by a number of other tissues and cells, including 16 In vivo, catecholamines inhibit the production of pro-inflammatory cytokines and contribute to the skewing of the immune system towards Th2 cell development. While lymphocyte function is predominantly modulated by α 2 -adrenergic receptors, 17 it is thought that α 1 -adrenergic receptors may also play at least a partial role. 18 The present study indicates that the prevalence of Treg cells, a lymphocyte subtype responsible for controlling the adaptive immune response, is increased after 3 months of doxazosin therapy in patients with type 2 diabetes. This increase in prevalence of Treg cells may be of major clinical importance. While the significance of low numbers of Treg cells in the progression and complications of atherosclerosis is supported by both animal and human data, 19 -21 no therapeutic approach exists to promote an increase in this particular cell type. The present study indicates that the modulation of adrenergic receptors in type 2 diabetic patients may be a way to produce higher numbers of Treg cells. The mechanism behind this phenomenon is, however, currently unclear; improved blood glucose control, immunomodulatory action on innate immune cells and/or even a direct effect on α 1 -adrenergic receptors may potentially contribute to an increase in the numbers of Treg cells.
As well as an increase in the number of Treg cells, the number of activated CD4 + and CD8 + T-cells decreased during doxazosin therapy in the present study. This may be characteristic of a systemic antiinflammatory action, although this was not reflected by the stable levels of hsCRP observed during the course of the study, which may have been due to a low baseline level. The limited data from the present study do not allow us to determine definitively whether this lower activation is due to an increased number of Treg cells, the result of the inhibition of α 1 -adrenergic receptors, or an improved metabolic state.
In conclusion, the present study indicates an immunomodulatory action of α 1 -adrenergic receptor inhibitor therapy in type 2 diabetic patients. Further studies are required to establish whether this effect contributes to protection against cardiovascular complications in this highrisk population.
